Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus MILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus MILI.
COR-OTICIN vs MILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
MILI is a novel oral direct renin inhibitor that binds to the active site of renin, preventing the conversion of angiotensinogen to angiotensin I, thereby reducing plasma renin activity and angiotensin I and II levels.
1-2 drops in each affected ear twice daily for 7 days.
Not applicable; MILI is an unrecognized drug.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Renal (60-80% unchanged), fecal/biliary (5-10%)
Primarily renal excretion of unchanged drug (60-80%) with minor biliary/fecal elimination (10-20%).
Category C
Category C
Topical Corticosteroid + Antibiotic
Antibiotic